Swissmedic has granted Orphan Drug Status for resminostat for treatment of cutaneous T-cell lymphoma (CTCL) ODS benefits include reduced fees in Switzerland Planegg-Martinsried, Germany, 16 July 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage CTCL, received notification from the Swiss Agency for Therapeutic Products […]